Symptomatic Event Reduction with Extended-Duration Betrixaban in Acute Medically Ill Hospitalized Patients
Conclusion In an mITT analysis of all patients administered study drug, extended duration betrixaban reduced the primary endpoint as well as symptomatic events. In an as treated analysis, 80 mg of betrixaban reduced VTE related death.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Heart | Lovenox | Pulmonary Thromboembolism | Study | Thrombosis | Ultrasound